Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
P16410
UPID:
CTLA4_HUMAN
Alternative names:
Cytotoxic T-lymphocyte-associated antigen 4
Alternative UPACC:
P16410; A0N1S0; E9PDH0; O95653; Q0PP65; Q52MC1; Q53TD5; Q5S005; Q8WXJ1; Q96P43; Q9UKN9
Background:
Cytotoxic T-lymphocyte protein 4 (CTLA-4), also known as Cytotoxic T-lymphocyte-associated antigen 4, plays a pivotal role in the immune system as a major negative regulator of T-cell responses. Its interaction with natural B7 family ligands, CD80 and CD86, showcases a stronger affinity compared to the stimulatory coreceptor CD28, highlighting its critical function in modulating immune responses.
Therapeutic significance:
CTLA-4's involvement in diseases such as Systemic lupus erythematosus, Type 1 diabetes mellitus 12, Celiac disease 3, and Immune dysregulation with autoimmunity, immunodeficiency, and lymphoproliferation underscores its potential as a therapeutic target. Understanding the role of CTLA-4 could open doors to potential therapeutic strategies, offering hope for patients suffering from these autoimmune disorders.